Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
Di Biagio
Antonio
A
Rosso
Raffaella
R
Bruzzone
Bianca
B
Cenderello
Giovanni
G
Dentone
Chiara
C
Mularoni
Alessandra
A
Ferrea
Giuseppe
G
Icardi
Giancarlo
G
Viscoli
Claudio
C
D002219:Carbamates / Q000494:pharmacology / Q000627:therapeutic use*; D000069454:Darunavir; D024882:Drug Resistance, Viral / Q000235:genetics*; D004359:Drug Therapy, Combination; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D019438:Ritonavir; D000069454:Darunavir